3:36 PM
 | 
Nov 21, 2012
 |  BC Extra  |  Company News

Sequenom jumps on recommendation for cell-free fetal DNA testing

Sequenom Inc. (NASDAQ:SQNM) jumped $0.50 (14%) to $4.19 on Wednesday after the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine recommended late Tuesday that physicians offer cell-free fetal DNA testing to women at increased risk of aneuploidy. In a joint...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >